Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Raises Price Target to $75

Benzinga Newsdesk www.benzinga.com Positive 69.9%

Neg 0% Neu 0% Pos 69.9%

Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and raises the price target from $74 to $75.